Want to see REVB full AI Analyst Report?
Top Page
Revelation Biosciences
(NASDAQ:REVB)
Select Model
Select Model
Rating:42Neutral
Price Target:
$3.50
▲(250.00% Upside)
Action:Reiterated
Date:10/21/26
The score is primarily held down by weak financial performance (no revenue, recurring losses, and significant ongoing cash burn) and bearish technical momentum (negative MACD with deeply oversold RSI/Stoch). Low leverage and improved equity provide some balance-sheet support, but valuation is not compelling given losses and no dividend yield data.
Positive Factors
Low Leverage
Very low leverage gives Revelation Biosciences a stronger solvency position than its loss profile alone would suggest. Limited debt reduces interest and refinancing pressure, preserving more flexibility to direct available capital toward clinical development and operating needs.
Negative Factors
No Revenue
Zero revenue means the business has not yet demonstrated commercial demand or an operating revenue engine. Until a product reaches the market, funding for research and development remains dependent on capital availability rather than internally generated sales.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low leverage gives Revelation Biosciences a stronger solvency position than its loss profile alone would suggest. Limited debt reduces interest and refinancing pressure, preserving more flexibility to direct available capital toward clinical development and operating needs.
Read all positive factors
Revelation Biosciences (REVB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.01M
Dividend YieldN/A
Average Volume (3M)16.43K
Price to Earnings (P/E)―
Beta (1Y)0.56
Revenue GrowthN/A
EPS Growth95.51%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-49.00
Shares Outstanding569,059
10 Day Avg. Volume37,490
30 Day Avg. Volume16,434
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.22
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-3.38
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit343.02
Enterprise Value/Ebitda0.62
Forecast
1Y Price Target
$16.00Price Target Upside1500.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-36.3
Revenue Forecast (FY)N/A
Revelation Biosciences Business Overview & Revenue Model
Company Description
Revelation Biosciences, Inc. is a biopharmaceutical firm currently in its clinical development phase, dedicated to the advancement and commercialization of treatments and diagnostic tools targeting the immune system. The company's therapeutic pipe...
Revelation Biosciences Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
46
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -19.82K | -27.06K | -27.92K | -25.05K | -40.01K | 0.00 |
| EBITDA | -10.90M | -9.04M | -7.95M | -8.63M | -10.84M | -11.93M |
| Net Income | -10.75M | -8.91M | -15.04M | -120.25K | -10.83M | -11.99M |
Balance Sheet | ||||||
| Total Assets | 12.50M | 11.58M | 6.62M | 12.21M | 5.50M | 2.04M |
| Cash, Cash Equivalents and Short-Term Investments | 11.48M | 10.70M | 6.50M | 11.99M | 5.25M | 1.27M |
| Total Debt | 739.92K | 746.78K | 0.00 | 0.00 | 0.00 | 16.75K |
| Total Liabilities | 2.43M | 2.72M | 1.91M | 5.56M | 4.45M | 2.14M |
| Stockholders Equity | 10.07M | 8.86M | 4.71M | 6.65M | 1.05M | -99.47K |
Cash Flow | ||||||
| Free Cash Flow | -9.44M | -8.27M | -18.34M | -7.29M | -11.22M | -11.22M |
| Operating Cash Flow | -9.33M | -8.27M | -18.32M | -7.29M | -11.22M | -11.09M |
| Investing Cash Flow | -111.51K | 0.00 | -19.17K | 0.00 | 0.00 | -131.96K |
| Financing Cash Flow | 15.75M | 12.47M | 12.85M | 14.03M | 15.20M | 8.00M |
Revelation Biosciences Technical Analysis
Negative
1.00
Price Trends
6.09
Negative
6.72
Negative
8.59
Negative
Market Momentum
-0.75
Positive
30.29
Neutral
24.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For REVB, the sentiment is Negative. The current price of 1 is below the 20-day moving average (MA) of 4.78, below the 50-day MA of 6.09, and below the 200-day MA of 8.59, indicating a bearish trend. The MACD of -0.75 indicates Positive momentum. The RSI at 30.29 is Neutral, neither overbought nor oversold. The STOCH value of 24.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for REVB.
Revelation Biosciences Risk Analysis
Revelation Biosciences disclosed 68 risk factors in its most recent earnings report. Revelation Biosciences reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Revelation Biosciences Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.56M | -0.16 | -166.67% | ― | ― | 88.77% | |
43 Neutral | $10.45M | -0.05 | -443.08% | ― | ― | 75.09% | |
42 Neutral | $2.01M | -0.07 | -100.19% | ― | ― | 95.51% | |
42 Neutral | $9.27M | -1.18 | -205.45% | ― | ― | 78.16% |
* Healthcare Sector Average
REVB
Revelation Biosciences
3.54
-32.58
-90.21%
GTBP
GT Biopharma
5.07
-12.29
-70.79%
DRMA
Dermata Therapeutics
0.72
-3.35
-82.36%
CERO
CERo Therapeutics Holdings
0.01
-1.87
-99.47%
PBM
Psyence Biomedical
3.66
-16.72
-82.04%
AZTR
Azitra Inc
1.53
-3.93
-71.98%
Revelation Biosciences Corporate Events
Business Operations and StrategyExecutive/Board Changes
Revelation Biosciences Grants Performance-Based Executive Stock Awards
Positive
Aug 19, 2026
On August 17, 2026, Revelation Biosciences’ compensation committee granted restricted stock awards to Chief Executive Officer James Rolke and Chief Financial Officer Chester S. Zygmont III under the company’s Amended and Restated 2021 ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.